aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Founded in Jupiter, United States, Cytonics is a biotechnology company dedicated to the research and development of diagnostics and therapeutics for osteoarthritis. Their core mission is to improve the diagnosis and treatment of musculoskeletal-related pain. The company's flagship product, the Fibronectin-Aggrecan Complex Test (FACT™), detects cartilage damage from osteoarthritis using joint fluid samples. This innovative diagnostic tool has been licensed to Synthes, which was later acquired by Johnson & Johnson, and has been utilized by numerous physicians.
Cytonics has garnered attention for its impactful contributions to the field of osteoarthritis diagnostics. The licensing of FACT™ to Synthes represents a significant milestone, demonstrating the product's clinical utility and commercial viability. The company's work has improved the ability of healthcare providers to diagnose and treat osteoarthritis, thereby enhancing patient outcomes. Through ongoing innovation and strategic partnerships, Cytonics continues to influence the biotechnology landscape positively.
Operating Status
Active
Main Product(s)
Diagnostic Assays
Technology
Biotech
Tags
Healthtech
Model Types
Licensing, Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Cytonics founded?
Cytonics was founded in 2006.
Where is Cytonics's headquarters located?
Cytonics's headquarters is located in Jupiter, FL, US.
How many employees does Cytonics have?
Cytonics has 75 employees as of Feb 5, 2024.
How much has Cytonics raised to-date?
As of July 05, 2023, Cytonics has raised a total of $5.7M (USD) since May 18, 2019.
Add Comparison
Total Raised to Date
$5.7M
USD
Last Update May 18, 2019
Total Employees Over Time
75
As of Feb 2024
Cytonics Address
658 W Indiantown Rd
suite 214
Jupiter,
Florida
33458-7535
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts